title: Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor.
abstract: Bone metastasis is a common event during breast cancer progression. Recently, mesenchymal stem cells (MSCs) have been implicated in the metastasis of primary mammary cancer. Given that bone is the native environment for MSCs, we hypothesized MSCs facilitate the homing of circulating mammary cancer cells to the bone. To test this hypothesis, we examined in vitro whether bone derived MSCs from FVB mice could influence the migration of syngeneic murine mammary cancer cell lines derived from the polyoma virus middle-T (PyMT) model of mammary gland tumorigenesis. Our data show that conditioned media derived from MSCs significantly enhanced the migration of PyMT mammary cancer cell lines. Analysis of conditioned media using a cytokine array revealed the presence of numerous cytokines in the MSC conditioned media, most notably, the murine orthologs of CXCL1 and CXCL5 that are cognate ligands of the CXCR2 receptor. Further investigation identified that: (1) CXCL1, CXCL5 and CXCR2 mRNA and protein were expressed by the MSCs and PyMT cell lines and; (2) neutralizing antibodies to CXCL1, CXCL5 and CXCR2 or a CXCR2 small molecule inhibitor (SB265610) significantly abrogated the migratory effect of the MSC conditioned media on the PyMT cells. Therefore, in vitro evidence demonstrates that bone derived MSCs play a role in the migration of mammary cancer cells, a conclusion that has potential implications for breast to bone metastasis in vivo.
authors: Department of Orthopaedics and Rehabilitation, Vanderbilt University, Nashville, TN 37232, USA.
authors: Jennifer L
authors: JL
authors: Halpern
authors: Amy
authors: A
authors: Kilbarger
authors: Conor C
authors: CC
authors: Lynch
references: Gene Ther. 2008 May;15(10):730-8
references: 18401438
references: Cancer Res. 2009 Aug 15;69(16):6747-55
references: 19679556
references: J Biol Chem. 2004 Nov 19;279(47):49259-67
references: 15364949
references: Annu Rev Immunol. 2004;22:891-928
references: 15032599
references: Cancer Lett. 2007 Oct 28;256(2):137-65
references: 17629396
references: BMC Cancer. 2010 Jun 12;10:283
references: 20540789
references: Nature. 2007 Oct 4;449(7162):557-63
references: 17914389
references: Prostate. 2006 Dec 1;66(16):1721-8
references: 16941672
references: Hum Gene Ther. 2010 Sep;21(9):1045-56
references: 20565251
references: Cancer Cell. 2003 Jun;3(6):537-49
references: 12842083
references: Clin Exp Metastasis. 2006;23(7-8):345-56
references: 17136574
references: Int J Cancer. 1997 Sep 26;73(1):94-103
references: 9334815
references: Clin Cancer Res. 2010 Aug 1;16(15):3875-86
references: 20505188
references: Cancer Cell. 2008 Jan;13(1):23-35
references: 18167337
references: FASEB J. 2007 Oct;21(12):3197-207
references: 17496162
references: Immunobiology. 2004;209(3):225-33
references: 15518334
references: J Biol Chem. 2010 Nov 12;285(46):35645-53
references: 20826809
references: Cancer Res. 2008 Aug 1;68(15):6251-9
references: 18676849
references: Leukemia. 2008 May;22(5):941-50
references: 18305549
references: Am J Pathol. 2010 Aug;177(2):873-83
references: 20558574
references: Oncogene. 2003 Jan 16;22(2):256-65
references: 12527894
references: J Invest Dermatol. 2000 Aug;115(2):234-44
references: 10951241
references: Exp Cell Res. 2004 May 1;295(2):395-406
references: 15093739
references: J Bone Miner Res. 2005 Feb;20(2):318-29
references: 15647826
references: Cancer Res. 2011 Jan 15;71(2):614-24
references: 21224357
references: J Immunol. 1988 Jul 15;141(2):575-9
references: 3290341
references: Cancer. 2003 Feb 1;97(3 Suppl):848-53
references: 12548585
references: Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18366-71
references: 19017790